Efficacy and safety of viva QS capsule for nicotine addiction in Malaysian adult smokers
We conducted a randomised, double-blind, placebo-controlled study to evaluate the effectiveness of Viva QS® capsule, a supplement consisting of twelve herbs, for the management of nicotine addiction. Smokers meeting study criteria were recruited into the study. Follow-up was undertaken for 6 mon...
| Main Authors: | , , , , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English |
| Published: |
2010
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/22330/ http://irep.iium.edu.my/22330/ http://irep.iium.edu.my/22330/4/pp18.pdf |
| Summary: | We conducted a randomised, double-blind, placebo-controlled study to evaluate the effectiveness of
Viva QS® capsule, a supplement consisting of twelve herbs, for the management of nicotine addiction.
Smokers meeting study criteria were recruited into the study. Follow-up was undertaken for 6 months,
with three assessment time points for smoking status andwithdrawal symptoms. Brief counseling was
provided at each follow-up via telephone call at week 4 and 12. At week 24, face-to-face follow-up was
done and self-reported abstinence was validated by measuring expired carbon monoxide level and
cotinine in urine and/or saliva samples. Result: Of 155 smokers recruited, mean age was 35.2 ± 8.36
years. Mean baseline Fagerström test for nicotine dependence (FTND) score was 5.03 ± 1.39. 7-days
point prevalence quit rate was 22.4% at week 24 [Viva QS = 30.7% vs. placebo = 13.9%]; p = 0.015; OR
= 2.74 (CI =1.197-6.282), 34.7% at week 12 [42.7% vs. 26.2%; p = 0.038, OR = 2.08 (CI = 1.04-4.16)
and 24.5% at week 12 [32% vs. 16.7%]; p =0.031; OR = 2.35 (CI = 1.07-5.17). Most common adverse
events reported were sore throat (Viva QS =28.8% vs. placebo = 36.6%), dry mouth (17.8% vs. 16.9%)
and cough (11% vs. 8.4%) There were no significant differences in all adverse events reported by subjects
in both groups. Conclusion: Viva QS ® at least doubled smoking cessation rate vs. placebo in smokers
with moderate to high level ofnicotine dependence without any significant adverse effects. |
|---|